Ph.D Frank Yocca - 15 Jun 2026 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)

Reporting relationship: Chief Scientific Officer
Issuer ticker: BTAI
Reported as of: 15 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Jun 2026, 20:00:27 UTC
Prior SEC filing: 22 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Richard Steinhart, as Attorney-in-Fact for Frank Yocca, Ph.D

Key filing fact

Ph.D Frank Yocca filed Form 4 for BioXcel Therapeutics, Inc. (BTAI) on 17 Jun 2026.

Key facts

This page summarizes Ph.D Frank Yocca's Form 4 filing for BioXcel Therapeutics, Inc. (BTAI).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 17 Jun 2026, 20:00.

Change

Previous filing in this sequence was filed on 22 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001733272 Primary reporting owner

Yocca Frank

Relationship: Chief Scientific Officer
Address: C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, 12TH FLOOR, NEW HAVEN
Signature: /s/ Richard Steinhart, as Attorney-in-Fact for Frank Yocca, Ph.D
Signature date: 17 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BTAI transaction

Common Stock

Options Exercise

Transaction value
Shares: +35
Change %: +0.13%
Price
Shares after: 26,210
Date: 15 Jun 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BTAI transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -35
Change %: -14%
Price: $0.000000^*
Shares after: 212
Date: 15 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 35
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

Footnote F2

On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.